Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) was upgraded by equities researchers at Oppenheimer from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, Marketbeat reports.
Other analysts have also issued reports about the stock. Maxim Group lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Wall Street Zen cut shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Piper Sandler downgraded shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 price objective for the company. in a research report on Thursday, July 30th. HC Wainwright restated a “neutral” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Capricor Therapeutics has an average rating of “Hold” and a consensus target price of $29.15.
Get Our Latest Stock Analysis on CAPR
Capricor Therapeutics Stock Performance
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). As a group, equities analysts forecast that Capricor Therapeutics will post -1.65 earnings per share for the current fiscal year.
Insider Transactions at Capricor Therapeutics
In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total transaction of $732,158.00. Following the sale, the chief financial officer owned 11,223 shares in the company, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 25,000 shares of company stock valued at $759,158. Corporate insiders own 9.20% of the company’s stock.
Institutional Trading of Capricor Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its stake in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after buying an additional 557 shares in the last quarter. KBC Group NV purchased a new position in shares of Capricor Therapeutics in the first quarter valued at about $44,000. ACT Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $43,000. Nuveen LLC boosted its stake in shares of Capricor Therapeutics by 2.1% in the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after acquiring an additional 1,878 shares during the period. Finally, State of Wyoming boosted its stake in shares of Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 1,913 shares during the period. 21.68% of the stock is currently owned by institutional investors.
Capricor Therapeutics News Summary
Here are the key news stories impacting Capricor Therapeutics this week:
- Positive Sentiment: The FDA extended deramiocel’s review by three months and set a new PDUFA target action date of November 22, 2026. Capricor said the extension allows the agency to review additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication. The continued review means the application remains active and gives the company more time to address regulatory questions. Capricor Therapeutics Announces Extension of PDUFA Target Action Date
- Neutral Sentiment: Multiple reports said the FDA’s decision followed new data submitted by Capricor. While the added analyses could improve the application, the three-month delay postpones a potential approval decision and leaves the commercial outlook uncertain. US FDA Extends Review of Capricor’s Muscle Disorder Therapy
- Negative Sentiment: Several law firms announced securities-fraud class actions or investor notices against Capricor and certain executives. The lawsuits allege that the company made material misstatements or omissions about deramiocel’s clinical data, the HOPE-3 statistical analysis plan, FDA compliance, and the path toward approval. The allegations have not been proven, but the litigation creates legal, financial, and reputational risks; investors have until September 28, 2026 to seek lead-plaintiff status. CAPR Investor Losses Securities Class Action Announcement
- Negative Sentiment: Investor concerns intensified after FDA briefing materials reportedly raised questions about changes to the HOPE-3 statistical analysis plan and the integrity of supporting data. Reports linked those concerns to a prior severe decline in CAPR shares, increasing uncertainty around approval probability and valuation. Levi and Korsinsky Capricor Investor Notice
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Read More
- Five stocks we like better than Capricor Therapeutics
- Beyond Big Tech: 3 Non-Tech Earnings Winners to Watch
- 3 Contrarian Trades for a Market That Looks Too Hot
- The Bull Case for D-Wave After a Disappointing Earnings Season
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
